Please assess the completion status of the following clinical trial:

Trial Title: A Study of Taurine in Patients With First-episode Psychosis Receiving Antipsychotic Treatment

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2/PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Male and females~* Between 18 and 25 years of age~* First Episode Psychosis~* Attending ORYGEN Youth Health, a geographical based catchment area service for young people aged between 15 and 25.~Exclusion Criteria:~* Organic disorders presenting with a psychotic syndrome (e.g. brain tumour, temporal lobe epilepsy, HIV encephalopathy)~* Mental retardation (unable and/or unlikely to give appropriate information of symptomatology or side-effects (IQ approximately lower than 80)~* History of clinically significant physical illness (e.g. terminal cancer, renal dialysis)~* History of brain surgery~* History of brain infarction~* Pregnant or lactating women or women of childbearing potential not using an acceptable method of contraception.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 25 Years
- Healthy Volunteers: f

Study Arms:
- Placebo pill (Type: PLACEBO_COMPARATOR): 4 placebo pills daily for 3 months
- Taurine 4g (Type: EXPERIMENTAL): Taurine 4g daily comprising four 1g pills

Based on this trial design, predict the completion outcome and termination type (if applicable).